[144] Tarsus Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Tarsus Pharmaceuticals filed a Form 144 reporting a proposed sale of 6,000 shares of common stock through Merrill Lynch in Newport Beach with an aggregate market value of $300,000. The filing lists 42,214,106 shares outstanding and an approximate sale date of 08/11/2025. The shares were acquired on 01/13/2017 in a private placement from Tarsus Pharmaceuticals and were paid for in cash. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Small proposed sale of 6,000 shares (~$300k), immaterial relative to outstanding shares and unlikely to move the market.

The filing shows a proposed sale of 6,000 shares with an aggregate market value of $300,000. Against the reported 42,214,106 shares outstanding, the position represents approximately 0.014% of outstanding shares, indicating a negligible dilution or float impact. No sales were reported in the prior three months. The transaction will be executed through Merrill Lynch in Newport Beach and is labeled for approximately 08/11/2025. Impact classification: not impactful.

Corporate Governance Expert

TL;DR: Form appears procedurally complete with required seller representation; seller identity is not provided in the visible fields.

The notice includes required details about acquisition (private placement on 01/13/2017) and payment method (cash), and it contains the standard attestation regarding undisclosed material adverse information. The filing lists the executing broker (Merrill Lynch) and an approximate sale date (08/11/2025). The document does not disclose the seller's name in the provided fields, which limits stakeholder ability to assess insider status or potential reasons for sale. Impact classification: not impactful.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 520 Newport Center Drive Floor 20 Newport Beach CA 92660	6000	300000.00	42214106	08/11/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/13/2017	Private Placement	Tarsus Pharmaceuticals, Inc.			6000	01/13/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TARS Form 144 report?

The Form 144 reports a proposed sale of 6,000 common shares of Tarsus Pharmaceuticals (TARS) with an aggregate market value of $300,000.

When is the proposed sale scheduled for TARS?

The filing lists an approximate sale date of 08/11/2025.

How and when were the shares being sold on Form 144 acquired?

The shares were acquired on 01/13/2017 in a private placement from Tarsus Pharmaceuticals and paid for in cash.

How many TARS shares are outstanding according to the filing?

The filing reports 42,214,106 shares outstanding.

Were any TARS securities sold in the past three months by this seller?

The filing states Nothing to Report for securities sold during the past three months.

Who is the broker handling the proposed TARS sale?

The broker named in the filing is Merrill Lynch at 520 Newport Center Drive, Newport Beach, CA.

Does the filing identify the person selling the shares?

The provided content does not display the name of the person for whose account the securities are to be sold.